EyeGene Inc is a Korea-based company primarily engaged in research and development in the medical and pharmaceutical fields. The Company is mainly engaged in the research and development of messenger ribonucleic acid (mRNA)-based vaccines. The Company also develops novel treatments for ophthalmic diseases, including treatments for macular degeneration and diabetic retinopathy, as well as adeno-associated virus (AAV) gene therapy targeting rare retinal diseases. In addition, the Company develops a quadrivalent meningococcal vaccine and recombinant botulinum toxin.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
14/08/26	KRW 2,015.00	-0.74%	171,592
13/08/26	KRW 2,030.00	+3.05%	579,399
12/08/26	KRW 1,970.00	+1.03%	257,278
11/08/26	KRW 1,950.00	+6.97%	322,118

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. 14/08/2026			5-day change	1st Jan Change
2,015.00 ^KRW	-0.74%		+10.53%	+15.87%

16/09/25	Eyegene Inc to conduct capital increase of 32 billion won for operational funds	RE
21/12/23	EyeGene Inc. announced that it has received KRW 15.000001688 billion in funding from BMI Korea Co., Ltd.	CI

Market Cap	87.11B 61.61M 53.19M 49.9M 45.45M 85.46M 5.89B 86.65M 585M 229M 2.95B 231M 226M 9.82B	P/E 2024	-5.71x	P/E 2025	-3.1x
Enterprise Value	42.17B 29.83M 25.75M 24.16M 22M 41.37M 2.85B 41.95M 283M 111M 1.43B 112M 110M 4.75B	EV / Sales 2024	11.6x	EV / Sales 2025	8.48x
Free-Float	70.86%	Yield 2024 *	-	Yield 2025	-

16/09/25	Eyegene Inc to conduct capital increase of 32 billion won for operational funds	RE
21/12/23	EyeGene Inc. announced that it has received KRW 15.000001688 billion in funding from BMI Korea Co., Ltd.	CI
13/12/23	EyeGene Inc. announced that it expects to receive KRW 15.000001688 billion in funding from BMI Korea Co., Ltd.	CI
15/05/23	EyeGene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
15/03/23	EyeGene Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
07/04/22	EyeGene Inc.(KOSDAQ:A185490) dropped from S&P Global BMI Index	CI
05/10/21	Maravai LifeSciences : Says Unit TriLink To Supply Proprietary Technology to EyeGene for Production of COVID-19 Vaccine	MT
20/09/21	EyeGene Inc.(KOSDAQ:A185490) added to S&P Global BMI Index	CI
18/09/20	EyeGene Inc. announced that it has received KRW 22 billion in funding from a group of investors	CI
16/09/20	EyeGene Inc. announced that it expects to receive KRW 22 billion in funding from a group of investors	CI
23/09/19	EyeGene Inc.(KOSDAQ:A185490) dropped from S&P Global BMI Index	CI
28/09/18	EyeGene Inc. announced that it has received KRW 29.9998664 billion in funding from Meritz Securities Co., Ltd., Investment Arm, IBK Capital Corporation, Korea Investment & Securities Co., Ltd., Investment Arm	CI
20/09/18	EyeGene Inc. announced that it expects to receive KRW 29.9998664 billion in funding from a group of investors	CI

1 day	-0.74%
1 week	+10.53%
Current month	+37.17%
1 month	+35.14%
3 months	+39.06%
6 months	+40.22%
Current year	+15.87%

EyeGene Inc. Stock

Stocks

A185490

KR7185490000

Pharmaceuticals

Valuation: EyeGene Inc.

Chart: EyeGene Inc.

Latest news : EyeGene Inc.

Quotes and Performance

Course Extremes

Managers and Directors: EyeGene Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	1,895	2,200
1 month	1,393	2,200
Current year	1,182	2,805
1 year	1,182	3,180
3 years	1,182	4,895
5 years	1,182	60,200
10 years	1,182	60,200

Manager	Title	Age	Since
Suk-Keun Choi CEO	Chief Executive Officer	59	20/02/2024
Myeong-Jae Lee DFI	Director of Finance/CFO	56	01/05/2012
Won-Il Yoo PSD	President	63	23/06/2000

Director	Title	Age	Since
Won-Il Yoo BRD	Director/Board Member	63	23/06/2000
Myeong-Jae Lee BRD	Director/Board Member	56	20/02/2024
Dal-Hyun Kim BRD	Director/Board Member	64	13/05/2022

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/4/24	Kwang-In Lee	Buy		8,019	0.0297%
10/4/24	Kwang-In Lee	Buy		12,297	0.0455%
12/3/24	Won-Il Yoo	Buy	Chairperson	1,000	0.0037%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EYEGENE INC.	-0.74%	+10.53%	-35.31%	-45.17%	61.61M
ELI LILLY AND COMPANY	+0.25%	-3.96%	+68.73%	+120.06%	1,055B
JOHNSON & JOHNSON	+0.78%	+0.21%	+48.53%	+50.78%	632B
ABBVIE INC.	+0.35%	+0.95%	+21.11%	+66.86%	442B
ROCHE HOLDING AG	+0.91%	-2.60%	+40.35%	+40.87%	351B
NOVARTIS AG	+0.55%	-1.48%	+23.73%	+38.72%	290B
ASTRAZENECA PLC	+0.35%	-2.01%	-1.12%	+8.89%	243B
AMGEN INC.	+1.00%	+0.52%	+41.46%	+58.95%	227B
NOVO NORDISK A/S	-0.22%	-5.11%	-16.12%	-53.40%	200B
GILEAD SCIENCES, INC.	+0.40%	+4.40%	+17.36%	+81.59%	172B
Average	+0.36%	-0.25%	+20.87%	+36.82%	361.26B
Weighted average by Cap.	+0.48%	-1.87%	+39.43%	+64.43%

	2024	2025
Net sales	3.36B 2.37M 2.05M 1.92M 1.75M 3.29M 227M 3.34M 22.54M 8.83M 114M 8.91M 8.72M 378M	3.57B 2.52M 2.18M 2.04M 1.86M 3.5M 241M 3.55M 23.95M 9.39M 121M 9.47M 9.27M 402M
Net income	-12.13B -8.58M -7.41M -6.95M -6.33M -11.9M -820M -12.06M -81.45M -31.92M -411M -32.21M -31.51M -1.37B	-15.71B -11.11M -9.59M -9M -8.19M -15.41M -1.06B -15.62M -105M -41.33M -532M -41.71M -40.8M -1.77B
Net Debt	-30.11B -21.29M -18.38M -17.25M -15.71M -29.54M -2.04B -29.95M -202M -79.23M -1.02B -79.95M -78.22M -3.39B	-44.94B -31.78M -27.44M -25.74M -23.45M -44.09M -3.04B -44.7M -302M -118M -1.52B -119M -117M -5.06B